HAEMATO AG Corporate News: Preliminary IFRS results 2019

[et_pb_section admin_label=“section“] [et_pb_row admin_label=“row“] [et_pb_column type=“4_4″][et_pb_text admin_label=“Text“]

HAEMATO AG Corporate News:
HAEMATO AG was able to achieve sales of 197.8 mEUR and an EBITDA of 1.9 mEUR for the fiscal year 2019 according to preliminary IFRS financial statements.

HAEMATO AG, Berlin (ISIN: DE0006190705), achieved consolidated sales of 197.8 mEUR (previous year: 274.1 mEUR), an operating result (EBIT) of -20 kEUR (previous year: 6.6 mEUR) and net profit of -1.17 mEUR (previous year: 6.3 mEUR) in the financial year 2019.

After generating consolidated sales of 94.0 mEUR in the first half of 2019, the Group sales in the fourth quarter of 2019 reached 56.0 mEUR. This represents an increase of 17.2% as compared to sales for the third quarter of 2019.

The 2019 net profit will be affected by measurement of financial assets at fair value on the reporting date not affecting liquidity.

Favourable procurement opportunities in the last quarter of 2019 led to a temporary increase in inventories and the associated increase in liabilities. Nevertheless, the HAEMATO Group is well positioned with an equity ratio of 56.2% (previous year: 65.0%) and equity capital of 72.2 mEUR as of December 31, 2019.

As one of the leading providers of specialty pharmaceuticals, the HAEMATO Group benefits from competition in the primary healthcare market. The specialization in medicines for the treatment of chronic diseases and individual therapies gives grounds to expect a positive development in the future due to demographic developments.

Despite increasing sales in the last quarter of 2019 and a positive start in 2020, HAEMATO is not able to provide any realistic business projections due to the latest developments of the COVID-19 pandemic. Like the entire economy, HAEMATO is potentially subject to the effects of the COVID-19 pandemic and the respective impact the global measures may have on the economy. The unfolding negative impacts on the economy and the resulting consequences may also affect HAEMATO’s operating business. Precise effects will likely only be realized during the course of the year. The company’s Executive Board currently continues to assume that increased sales – compared to the previous year – can be achieved in 2020.

Today the Executive Board also decided on a proposal on the allocation of profits, according to which no dividend is to be distributed to shareholders for the financial year 2019. This is to be understood as a reaction to the 2019 result as well as a measure to secure and improve the HAEMATO Group’s liquidity, taking into account the uncertainties associated to the further developments in the COVID-19 pandemic.

About HAEMATO:
HAEMATO AG, founded in 1993, is a pharmaceutical company focusing on the growing markets of high-priced specialty pharmaceuticals in the indication areas of oncology and HIV as well as other chronic diseases.

HAEMATO AG is listed on the Basic Board (Open Market) of the Frankfurt Stock Exchange.
Key figures on the HAEMATO AG share:
Subscribed capital: EUR 22,867,154
Listed class of shares: bearer ordinary shares
ISIN: DE0006190705
WKN: 619070
Stock exchange code: HAE

[/et_pb_text][/et_pb_column] [/et_pb_row] [/et_pb_section]